New York, NY -- (SBWIRE) -- 01/03/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Mueller Water Products, Inc (NYSE:MWA), Targacept , Inc (NASDAQ:TRGT), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Apollo Investment Corp (NASDAQ:AINV)
Mueller Water Products, Inc (NYSE:MWA) showed a volume of 1.21 million shares by the end of last trade whereas the average volume of the stock remained 1.05 million shares. The stock opened the session at $9.31 but then moved to $9.19. At that price, the stock showed a negative performance of -1.92%. Mueller Water Products, Inc. is a manufacturer and marketer of products and services used in the transmission, distribution and measurement of water. The Company’s product portfolio includes engineered valves, fire hydrants, metering products and systems, leak detection and pipe condition assessment services and a range of pipe fittings, couplings and hangers for heating, ventilation and air conditioning (HVAC). The Company operates in two segments.
Will MWA Get Buyers Even After The Recent Rally? Find Out Here
Targacept , Inc (NASDAQ:TRGT) opened the session at $4.15 and closed the session at $4.16. The stock showed a positive performance of 0.24% in previous trading session. Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas.
For How Long TRGT will fight for Profitability? Read This Trend Analysis report
Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened the session at $0.26and closed the session at $0.275. The stock showed a positive performance of 3.77% in previous trading session. The beta of the stock remained 1.76. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development.
Why Should Investors Buy HEB After The Recent Gain? Just Go Here and Find Out
Apollo Investment Corp (NASDAQ:AINV) the stock decreased -0.65% and finished the session at $8.42. Traded with volume of 1.94 million shares in the prior session and the average volume of the stock remained 1.49 million shares. The beta of the stock remained 1.77. Apollo Investment Corporation (Apollo Investment) is a closed-end, non-diversified management investment company that has elected to be treated as a business development company. Its investment objective is to generate current income and capital appreciation. It invests primarily in various forms of debt investments, including senior secured loans, subordinated and mezzanine investments and/or equity in private middle market companies.
Will AINV Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)